202 related articles for article (PubMed ID: 36859276)
21. Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia.
Trarbach EB; Costa EM; Versiani B; de Castro M; Baptista MT; Garmes HM; de Mendonca BB; Latronico AC
J Clin Endocrinol Metab; 2006 Oct; 91(10):4006-12. PubMed ID: 16882753
[TBL] [Abstract][Full Text] [Related]
22. A case of Kallmann syndrome carrying a missense mutation in alternatively spliced exon 8A encoding the immunoglobulin-like domain IIIb of fibroblast growth factor receptor 1.
Miura K; Miura S; Yoshiura K; Seminara S; Hamaguchi D; Niikawa N; Masuzaki H
Hum Reprod; 2010 Apr; 25(4):1076-80. PubMed ID: 20139426
[TBL] [Abstract][Full Text] [Related]
23. Functional Characteristics of Novel FGFR1 Mutations in Patients with Isolated Gonadotropin-Releasing Hormone Deficiency.
Choi JH; Oh A; Lee Y; Kim GH; Yoo HW
Exp Clin Endocrinol Diabetes; 2021 Jun; 129(6):457-463. PubMed ID: 32485746
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing of patients with congenital anosmia.
Alkelai A; Olender T; Dode C; Shushan S; Tatarskyy P; Furman-Haran E; Boyko V; Gross-Isseroff R; Halvorsen M; Greenbaum L; Milgrom R; Yamada K; Haneishi A; Blau I; Lancet D
Eur J Hum Genet; 2017 Dec; 25(12):1377-1387. PubMed ID: 29255181
[TBL] [Abstract][Full Text] [Related]
25. Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland.
Laitinen EM; Vaaralahti K; Tommiska J; Eklund E; Tervaniemi M; Valanne L; Raivio T
Orphanet J Rare Dis; 2011 Jun; 6():41. PubMed ID: 21682876
[TBL] [Abstract][Full Text] [Related]
26. [Molecular genetics of Kallmann syndrome: an update].
Fu C; Feng Z; Liu RZ
Zhonghua Nan Ke Xue; 2011 Apr; 17(4):361-5. PubMed ID: 21548217
[TBL] [Abstract][Full Text] [Related]
27. Greater prevalence of PROKR2 mutations in Kallmann syndrome patients from the Maghreb than in European patients.
Sarfati J; Fouveaut C; Leroy C; Jeanpierre M; Hardelin JP; Dodé C
Eur J Endocrinol; 2013 Dec; 169(6):805-9. PubMed ID: 24031091
[TBL] [Abstract][Full Text] [Related]
28. Targeted Gene Panel Sequencing for Molecular Diagnosis of Kallmann Syndrome and Normosmic Idiopathic Hypogonadotropic Hypogonadism.
Kim JH; Seo GH; Kim GH; Huh J; Hwang IT; Jang JH; Yoo HW; Choi JH
Exp Clin Endocrinol Diabetes; 2019 Sep; 127(8):538-544. PubMed ID: 30216942
[TBL] [Abstract][Full Text] [Related]
29. Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life.
Sarfati J; Bouvattier C; Bry-Gauillard H; Cartes A; Bouligand J; Young J
Orphanet J Rare Dis; 2015 Jun; 10():71. PubMed ID: 26051373
[TBL] [Abstract][Full Text] [Related]
30. The prevalence of intragenic deletions in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.
Pedersen-White JR; Chorich LP; Bick DP; Sherins RJ; Layman LC
Mol Hum Reprod; 2008 Jun; 14(6):367-70. PubMed ID: 18463157
[TBL] [Abstract][Full Text] [Related]
31. Identification of two novel missense mutations in the KAL1 gene in Han Chinese subjects with Kallmann Syndrome.
Jap TS; Chiu CY; Lirng JF; Won GS
J Endocrinol Invest; 2011 Jan; 34(1):53-9. PubMed ID: 20530987
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel mutation in
García-García E; Fernández RM; Navarro-Moreno C; Gómez-Gila AL; Borrego S
J Pediatr Endocrinol Metab; 2022 Oct; 35(10):1306-1308. PubMed ID: 35932482
[TBL] [Abstract][Full Text] [Related]
33. Clinical genetics of Kallmann syndrome.
Dodé C; Hardelin JP
Ann Endocrinol (Paris); 2010 May; 71(3):149-57. PubMed ID: 20362962
[TBL] [Abstract][Full Text] [Related]
34. A dominant negative FGFR1 mutation identified in a Kallmann syndrome patient.
Luo H; Zheng R; Zhao Y; Wu J; Li J; Jiang F; Chen DN; Zhou XT; Li JD
Gene; 2017 Jul; 621():1-4. PubMed ID: 28411082
[TBL] [Abstract][Full Text] [Related]
35. Genetic analysis in patients with Kallmann syndrome: coexistence of mutations in prokineticin receptor 2 and KAL1.
Canto P; Munguía P; Söderlund D; Castro JJ; Méndez JP
J Androl; 2009; 30(1):41-5. PubMed ID: 18723471
[TBL] [Abstract][Full Text] [Related]
36. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.
Costa-Barbosa FA; Balasubramanian R; Keefe KW; Shaw ND; Al-Tassan N; Plummer L; Dwyer AA; Buck CL; Choi JH; Seminara SB; Quinton R; Monies D; Meyer B; Hall JE; Pitteloud N; Crowley WF
J Clin Endocrinol Metab; 2013 May; 98(5):E943-53. PubMed ID: 23533228
[TBL] [Abstract][Full Text] [Related]
37. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.
Kim HG; Kurth I; Lan F; Meliciani I; Wenzel W; Eom SH; Kang GB; Rosenberger G; Tekin M; Ozata M; Bick DP; Sherins RJ; Walker SL; Shi Y; Gusella JF; Layman LC
Am J Hum Genet; 2008 Oct; 83(4):511-9. PubMed ID: 18834967
[TBL] [Abstract][Full Text] [Related]
38. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism.
Pitteloud N; Acierno JS; Meysing A; Eliseenkova AV; Ma J; Ibrahimi OA; Metzger DL; Hayes FJ; Dwyer AA; Hughes VA; Yialamas M; Hall JE; Grant E; Mohammadi M; Crowley WF
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6281-6. PubMed ID: 16606836
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of KAL-1, GnRH-R, NELF and EBF2 genes in a series of Kallmann syndrome and normosmic hypogonadotropic hypogonadism patients.
Trarbach EB; Baptista MT; Garmes HM; Hackel C
J Endocrinol; 2005 Dec; 187(3):361-8. PubMed ID: 16423815
[TBL] [Abstract][Full Text] [Related]
40. Reversible congenital hypogonadotropic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations.
Laitinen EM; Tommiska J; Sane T; Vaaralahti K; Toppari J; Raivio T
PLoS One; 2012; 7(6):e39450. PubMed ID: 22724017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
